Meeting Banner
Abstract #3061

Hybrid C11 Choline PET/MRI in staging untreated high risk and very high risk prostate cancer patients at single institution: preliminary results

Kelly T Smith1, Akira Kawashima2, Mark D Tyson3, Erik P Castle4, Alvin Silva1, Yuxiang Zhou1, Michael C Roarke1, and Ming Yang1
1Radiology, Mayo Clinic Arizona, PHOENIX, AZ, United States, 2Radiology, Mayo Clinic Arizona, Phoenix, AZ, United States, 3Urology, Mayo Clinic Arizona, PHOENIX, AZ, United States, 4Urology, Mayo Clinic Arizona, Phoenix, AZ, United States

The most prevalent malignancy in US men is prostate cancer. Appropriate treatment regimen is dependent on accurate tumor staging. Pelvic multiparametric MR (mpMRI) is the established modality for tumor and nodal staging. C-11 choline is FDA approved in diagnosis of recurrent prostate cancer. Introduction of a hybrid time-of-flight PET/MR system affords the opportunity to perform a combined C-11 choline PET + mpMRI for prostate cancer staging. We feel this system would be beneficial in staging of treatment naïve high risk prostate cancer.

This abstract and the presentation materials are available to 2020 meeting attendees and eLibrary customers only; a login is required.

Join Here